- Cancer Care Team
Cancer Care Team
To deliver optimal patient outcomesProducts and Services
Cancer Type
Supplies & Tools
Scientific Focus
- Biopharma Partners
- Patients
- Education & Events
- Login
- Contact Us
OmniSeq® INSIGHT provides a comprehensive, easy-to-read report with clinical guidance for more precise, targeted therapies and trials for your patients.
From a single tumor biopsy, analyzed by advanced next generation sequencing (NGS) technology,
OmniSeq INSIGHT identifies treatment options in one comprehensive, easy-to-read report.
1
A single tissue sample provides complete insight into the tumor and its microenvironment.
2
The report provides comprehensive genomic and immune profiling for all solid tumors.
3
A summary of FDA-approved therapies, immunotherapies and eligible clinical trials tailored to your patient’s solid tumor.
List of patient-eligible clinical trials within 200 miles of patient’s physical address1
Result | Labcorp Oncology Omniseq INSIGHT | Foundation Medicine® FoundationOne®CDx | NeoGenomics® Neotype® Analysis Discovery Profile | Caris MI™ Profile Comprehensive Tumor Profiling | Tempus® XT V4 | |
---|---|---|---|---|---|---|
Genomic Profling | NGS for Targeted Therapy | 523 Genes | 324 Genes | 323 Genes | 700 at High Depth | 648 Genes |
RNA-Seq for Fusion Detection | Yes | No | Add on option | Whole Transcriptome | Whole Transcriptome | |
Tumor Signatures | Tumor Mutational Burden (TMB) | Yes | Yes | Yes | Yes | Yes |
Microsatellite Instability (MSI) | Yes | Yes | Yes | Yes | Yes | |
Tumor Micro-Environment | PD-L1 by IHC | Yes | Add on option | Yes | Yes | Add on option |
PD-L1/PD-L2 GEP* | Yes | No | No | No | No | |
CD3/CD8 GEP* | Yes | No | No | No | No | |
Immune Activation - Gene Expression by RNA-Seq | Yes | No | No | No | No | |
Tumor Infiltrating Lymphocytes (TILs) | Yes | No | No | No | No | |
Clinical Trials | Geocoded Clinical Trials for Targeted and Immunotherapy | Yes | Targeted Only Not Geocoded | Targeted Only Not Geocoded | Link to CT Connector (Chemo + Targeted Clinical Trials) | Targeted Only Geocoded But Not Tumor Specific |
Result: NGS for Targeted Therapy | |
Labcorp Oncology Omniseq INSIGHT | 523 Genes |
Foundation Medicine® FoundationOne®CDx | 324 Genes |
NeoGenomics® Neotype® Analysis Discovery Profile | 323 Genes |
Caris MI Profile™ Comprehensive Tumor Profiling | 700 at High Depth |
Tempus® XT V4 | 648 Genes |
Result: RNA-Seq for Fusion Detection | |
Labcorp Oncology Omniseq INSIGHT | Yes |
Foundation Medicine® FoundationOne®CDx | No |
NeoGenomics® Neotype® Analysis Discovery Profile | Add on option |
Caris MI Profile™ Comprehensive Tumor Profiling | Whole Transcriptome |
Tempus® XT V4 | Whole Transcriptome |
Result: Tumor Mutational Burden (TMB) | |
Labcorp Oncology Omniseq INSIGHT | Yes |
Foundation Medicine® FoundationOne®CDx | Yes |
NeoGenomics® Neotype® Analysis Discovery Profile | Yes |
Caris MI Profile™ Comprehensive Tumor Profiling | Yes |
Tempus® XT V4 | Yes |
Result: Microsatellite Instability (MSI) | |
Labcorp Oncology Omniseq INSIGHT | Yes |
Foundation Medicine® FoundationOne®CDx | Yes |
NeoGenomics® Neotype® Analysis Discovery Profile | Yes |
Caris MI Profile™ Comprehensive Tumor Profiling | Yes |
Tempus® XT V4 | Yes |
Result: PD-L1 by IHC | |
Labcorp Oncology Omniseq INSIGHT | Yes |
Foundation Medicine® FoundationOne®CDx | Add on option |
NeoGenomics® Neotype® Analysis Discovery Profile | Yes |
Caris MI Profile™ Comprehensive Tumor Profiling | Yes |
Tempus® XT V4 | Add on option |
Result: PD-L1/PD-L2 GEP* | |
Labcorp Oncology Omniseq INSIGHT | Yes |
Foundation Medicine® FoundationOne®CDx | No |
NeoGenomics® Neotype® Analysis Discovery Profile | No |
Caris MI Profile™ Comprehensive Tumor Profiling | No |
Tempus® XT V4 | No |
Result: CD3/CD8 GEP* | |
Labcorp Oncology Omniseq INSIGHT | Yes |
Foundation Medicine® FoundationOne®CDx | No |
NeoGenomics® Neotype® Analysis Discovery Profile | No |
Caris MI Profile™ Comprehensive Tumor Profiling | No |
Tempus® XT V4 | No |
Result: Immune Activation - Gene Expression by RNA-Seq | |
Labcorp Oncology Omniseq INSIGHT | Yes |
Foundation Medicine® FoundationOne®CDx | No |
NeoGenomics® Neotype® Analysis Discovery Profile | No |
Caris MI Profile™ Comprehensive Tumor Profiling | No |
Tempus® XT V4 | No |
Result: Tumor Infiltrating Lymphocytes (TILs) | |
Labcorp Oncology Omniseq INSIGHT | Yes |
Foundation Medicine® FoundationOne®CDx | No |
NeoGenomics® Neotype® Analysis Discovery Profile | No |
Caris MI Profile™ Comprehensive Tumor Profiling | No |
Tempus® XT V4 | No |
Result: Geocoded Clinical Trials for Targeted and Immunotherapy | |
Labcorp Oncology Omniseq INSIGHT | Yes |
Foundation Medicine® FoundationOne®CDx | Targeted Only Not Geocoded |
NeoGenomics® Neotype® Analysis Discovery Profile | Targeted Only Not Geocoded |
Caris MI Profile™ Comprehensive Tumor Profiling | Link to CT Connector (Chemo + Targeted Clinical Trials) |
Tempus® XT V4 | Targeted Only Geocoded But Not Tumor Specific |
*GEP - genomic expression profiling
Data as of June 16, 2021
Comprehensive Quick-Read Results
THERAPY CONSIDERATIONS
MARKER DETAILS
Clinical Trial Options
Sample requirements (include pathology report) |
---|
Formalin fixed paraffin embedded (FFPE) tissue
**Do not submit decalcified specimens, cytology smears or samples from hematologic malignancies** |
FFPE block (preferred) or 20 unbaked, positively charged, unstained slides cut a 5 µm plus one H&E |
Turnaround time: 12-14 Days |
See test menu for additional information
1. OmniSeq Bioinformatics Knowledgebase - data curation January 2021.